| 前收市價 | 533.00 |
| 開市 | 539.60 |
| 買盤 | 538.20 x 0 |
| 賣出價 | 539.40 x 0 |
| 今日波幅 | 538.20 - 544.80 |
| 52 週波幅 | 350.00 - 591.07 |
| 成交量 | |
| 平均成交量 | 5,387,236 |
| 市值 | 4.053B |
| Beta 值 (5 年，每月) | 2.58 |
| 市盈率 (最近 12 個月) | 12.52 |
| 每股盈利 (最近 12 個月) | 0.43 |
| 業績公佈日 | 2024年5月16日 |
| 遠期股息及收益率 | 0.05 (0.84%) |
| 除息日 | 2024年2月22日 |
| 1 年預測目標價 | 718.24 |
FortuneAviation results: European carriers EasyJet and Jet2 fly to new heights, while Airbus prepares to overtake Boeing as headwinds continue
It's been an eventful few days for aviation players—from Airbus to Heathrow. Here's how they fared.
ReutersUK's easyJet sees strong summer momentum, lifting shares
LONDON (Reuters) -British airline easyJet said it was confident travel demand would remain strong this summer, putting it on track for further growth and boosting its shares after it forecast a smaller-than-expected winter loss. Consumers in Europe are continuing to spend on trips despite rising fares and their incomes being squeezed by higher interest rates, and easyJet chief executive Johan Lundgren said there was "positive momentum" going into the key travel season. Shares in easyJet traded up 4% at 0800 GMT, but at 538 pence the stock is a long way off pre-pandemic levels of 1,300 pence, as worries linger over how long travel spend can keep rising.
ReutersExclusive-EasyJet talking to European Commission about taking over slots at Linate airport, CEO says
BRUSSELS (Reuters) -EasyJet is in talks with the European Commission about taking over slots at Milan's Linate airport that could be available as a result of Lufthansa teaming up with ITA Airways, the budget airline's chief executive said on Wednesday. The German carrier is seeking a 41% stake in the state-owned Italian rival for 325 million euros ($351.4 million) as part of a capital increase and expects a statement of objections from the Commission setting out concerns this month. Europe's competition enforcer warned earlier this year that the concessions initially offered by Lufthansa, which had said it was prepared to offer targeted remedies, were insufficient in scope and effectiveness to address competition concerns.
